Loading Events

« All Events

  • This event has passed.

Cycle 2: NIH R41, R42, R43, R44, U43, U44

January 5

DUE DATE: JANUARY 5, 2022

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R43/R44): This funding opportunity announcement (FOA) encourages applications from small business concerns for Small Business Innovation Research (SBIR) projects that propose innovative research and development of technology for cryogenic or other long-term preservation and revival of Drosophila and zebrafish genetic stocks. The proposed technologies should be reliable, reproducible and cost effective for the long-term preservation and revival of wild type and laboratory created genetic stocks.

Details

Date:
January 5
Event Category:

Details

Date:
January 5
Event Category: